Class Action Lawsuit Filed Against GSK plc: Investors Urged to Contact Pomerantz LLP
NEW YORK, March 30, 2025 – Pomerantz LLP, a leading securities law firm, announces that a class action lawsuit has been filed against GSK plc (“GSK” or the “Company”) (NYSE: GSK). The action was filed in the United States District Court for the Southern District of New York and docketed under 2:25-cv-02136. This class action seeks to represent purchasers of GSK securities who have suffered financial harm as a result of Defendants’ violations of the federal securities laws.
Allegations Against GSK
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:
- GSK was engaged in unlawful and improper marketing practices;
- GSK’s financial statements were materially false and misleading;
- GSK failed to implement and enforce effective internal controls;
- GSK’s disclosures regarding its pharmaceutical business, including its respiratory and HIV franchises, were materially false and misleading;
- GSK failed to timely disclose material information.
Effects on Investors
As a result of these alleged false statements, GSK investors suffered significant losses. The class action seeks to recover damages on behalf of all GSK investors who purchased securities between [Date 1] and [Date 2].
Effects on the World
The implications of this class action lawsuit extend beyond the affected investors. GSK, a multinational pharmaceutical company, is one of the world’s leading research-based biopharmaceutical companies, and its actions can have far-reaching consequences. The lawsuit raises concerns about the ethical conduct of pharmaceutical companies, the reliability of their financial statements, and the effectiveness of regulatory oversight. It also highlights the importance of transparency and accountability in corporate reporting.
Conclusion
The class action lawsuit against GSK plc serves as a reminder of the importance of truthful and accurate disclosures in the securities markets. Pomerantz LLP encourages investors to contact them if they believe they have suffered financial losses as a result of GSK’s alleged misrepresentations. The lawsuit also underscores the need for continued vigilance and enforcement in the pharmaceutical industry to protect consumers and investors alike.
